Skip to main content
Clinical Trials/NCT03285815
NCT03285815
Recruiting
Not Applicable

A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With a Localized Prostate Adenocarcinoma

National Cancer Center, Korea1 site in 1 country156 target enrollmentMay 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Adenocarcinoma
Sponsor
National Cancer Center, Korea
Enrollment
156
Locations
1
Primary Endpoint
BCFFS
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma

Detailed Description

For Proton therapy with prostate adenocarcinoma patients. Arm 1: Proton therapy 3CGE x 20days = Total 60 CGE for 4 weeks. Arm 2: Proton therapy 4.7CGE x 10days = Total 47 CGE for 2 weeks.

Registry
clinicaltrials.gov
Start Date
May 2016
End Date
December 2025
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kwan Ho Cho

Principal Investigator

National Cancer Center, Korea

Eligibility Criteria

Inclusion Criteria

  • Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0
  • ECOG performance status:0-1
  • Signed study specific informed consent prior to study entry.

Exclusion Criteria

  • Postoperative residual or recurrent tumor
  • Evidence of distant metastasis previous irradiation for the tumor in the same location
  • Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)

Outcomes

Primary Outcomes

BCFFS

Time Frame: up to 5 years from a initial follow-up

To evaluate biochemical failure-free survival (BCFFS)

Secondary Outcomes

  • EPIC (Extended Prostate Cancer Index Composite)(up to 5 years from a initial follow-up)
  • Acute/late toxicity (CTCAE v4.0)(up to 5 years from a initial follow-up)
  • Disease specific survival(up to 5 years from a initial follow-up)

Study Sites (1)

Loading locations...

Similar Trials